Rigel Announces Presentation at UCSD Frontiers of Clinical Investigation Symposium
Monday September 12, 7:30 am ET
SOUTH SAN FRANCISCO, Calif., Sept. 12 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that a presentation related to its research program in rheumatoid arthritis will be made at the University of California San Diego's (UCSD) Clinical Investigation Symposium -- Autoimmunity 2005: From Bench to Bedside, taking place September 15-17 at the Estancia Hotel in La Jolla, California.
ADVERTISEMENT
Details are as follows:
Presentation Time: Saturday, September 17, 2005, 8:15 a.m. PDT
Title: An Orally Bioavailable Inhibitor of Syk Kinase (R406) Inhibits, Dose Responsively, Human Basophil CD63 Expression Following Ex Vivo FCe Receptor Stimulation
Rigel has focused its rheumatoid arthritis program on the development of oral, safe, disease modifying anti-rheumatic drugs (DMARD's). The company's product candidates are intended to be used early in the course of the disease to prevent the progression of major bone and cartilage destruction. R788, an oral formulation of R406, is Rigel's lead product candidate. Phase I trial results, to date, have demonstrated that R788 was safe and well-tolerated. In preclinical studies, Rigel's compound greatly diminished the swelling and tissue destruction associated with rheumatoid arthritis.
About Rigel
Rigel's mission is to become a source of novel, small-molecule drugs to meet large, unmet medical needs. We have three product development programs: asthma/allergy, rheumatoid arthritis and cancer. Our strategy is to commence clinical trials with one lead compound each year and to develop a portfolio of product candidates for our own proprietary programs and with potential collaborative partners. |
